Recent advances in the management of Hodgkin lymphoma

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Hodgkin lymphoma (HL) is a rare cancer of the immune system that typically affects lymph nodes and sometimes other organs. Although the majority of patients can be potentially cured with the use of multi-agent chemotherapy and radiotherapy, a proportion of them will relapse or develop resistant disease for which treatment options are limited. In recent years, new agents have been developed and tested in HL with encouraging results. Two classes of drugs stand out as highly active in advanced HL based on recent study results: antibody-drug conjugates and programmed death 1 inhibitors. Clinical trials in HL with these agents have been completed in the past several years and the results have recently become available. In this review, we discuss the recent advances in the management of HL with a focus on strategies to decrease toxicity and a review of the two drug classes that have the potential to change the landscape of treatment of this disease.

Original languageEnglish (US)
Article number768
JournalF1000Research
Volume5
DOIs
StatePublished - 2016

Fingerprint

Hodgkin Disease
Pharmaceutical Preparations
Chemotherapy
Immune system
Radiotherapy
Toxicity
Antibodies
Immune System
Lymph Nodes
Clinical Trials
Recurrence
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Recent advances in the management of Hodgkin lymphoma. / Villasboas Bisneto, Jose (J.C.); Ansell, Stephen Maxted.

In: F1000Research, Vol. 5, 768, 2016.

Research output: Contribution to journalReview article

@article{7859ec34088545538e85f545dece8d68,
title = "Recent advances in the management of Hodgkin lymphoma",
abstract = "Hodgkin lymphoma (HL) is a rare cancer of the immune system that typically affects lymph nodes and sometimes other organs. Although the majority of patients can be potentially cured with the use of multi-agent chemotherapy and radiotherapy, a proportion of them will relapse or develop resistant disease for which treatment options are limited. In recent years, new agents have been developed and tested in HL with encouraging results. Two classes of drugs stand out as highly active in advanced HL based on recent study results: antibody-drug conjugates and programmed death 1 inhibitors. Clinical trials in HL with these agents have been completed in the past several years and the results have recently become available. In this review, we discuss the recent advances in the management of HL with a focus on strategies to decrease toxicity and a review of the two drug classes that have the potential to change the landscape of treatment of this disease.",
author = "{Villasboas Bisneto}, {Jose (J.C.)} and Ansell, {Stephen Maxted}",
year = "2016",
doi = "10.12688/f1000research.8301.1",
language = "English (US)",
volume = "5",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Recent advances in the management of Hodgkin lymphoma

AU - Villasboas Bisneto, Jose (J.C.)

AU - Ansell, Stephen Maxted

PY - 2016

Y1 - 2016

N2 - Hodgkin lymphoma (HL) is a rare cancer of the immune system that typically affects lymph nodes and sometimes other organs. Although the majority of patients can be potentially cured with the use of multi-agent chemotherapy and radiotherapy, a proportion of them will relapse or develop resistant disease for which treatment options are limited. In recent years, new agents have been developed and tested in HL with encouraging results. Two classes of drugs stand out as highly active in advanced HL based on recent study results: antibody-drug conjugates and programmed death 1 inhibitors. Clinical trials in HL with these agents have been completed in the past several years and the results have recently become available. In this review, we discuss the recent advances in the management of HL with a focus on strategies to decrease toxicity and a review of the two drug classes that have the potential to change the landscape of treatment of this disease.

AB - Hodgkin lymphoma (HL) is a rare cancer of the immune system that typically affects lymph nodes and sometimes other organs. Although the majority of patients can be potentially cured with the use of multi-agent chemotherapy and radiotherapy, a proportion of them will relapse or develop resistant disease for which treatment options are limited. In recent years, new agents have been developed and tested in HL with encouraging results. Two classes of drugs stand out as highly active in advanced HL based on recent study results: antibody-drug conjugates and programmed death 1 inhibitors. Clinical trials in HL with these agents have been completed in the past several years and the results have recently become available. In this review, we discuss the recent advances in the management of HL with a focus on strategies to decrease toxicity and a review of the two drug classes that have the potential to change the landscape of treatment of this disease.

UR - http://www.scopus.com/inward/record.url?scp=84978537564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978537564&partnerID=8YFLogxK

U2 - 10.12688/f1000research.8301.1

DO - 10.12688/f1000research.8301.1

M3 - Review article

VL - 5

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 768

ER -